Pembrolizumab
- CAS No.
- 1374853-91-4
- Chemical Name:
- Pembrolizumab
- Synonyms
- MK-3475;pembrolimumab;Pembrolizumab;Lambrolizumab;Pembrolizumab 25mg/ml;Pembrolizumab (anti-PD-1);PEMBROLIMUMAB PD-1 1374853-91-4;Research Grade Pembrolizumab(DHH02202);PembrolizumabQ: What is Pembrolizumab Q: What is the CAS Number of Pembrolizumab Q: What is the storage condition of Pembrolizumab Q: What are the applications of Pembrolizumab
- CBNumber:
- CB12744222
- Molecular Formula:
- Molecular Weight:
- 0
- MOL File:
- Mol file
- Modify Date:
- 2024/7/2 8:55:00
| storage temp. | Store at -80°C |
|---|---|
| form | Liquid |
| color | Colorless to light yellow |
| CAS DataBase Reference | 1374853-91-4 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H360-H372 |
| Precautionary statements | P260-P264-P270-P314-P501 |
Pembrolizumab Chemical Properties,Uses,Production
Uses
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities.
Mechanism of action
Pembrolizumab is a humanized monoclonal IgG4 kappa antibody directed against human cell surface PD-1 (programmed death receptor-1) on lymphocytes. The PD-1 receptor provides a critical “immune checkpoint,” which helps prevent the immune system from attacking itself. Certain tumors have a high expression of PD-L1(programmed death receptor ligand-1). Other tumor types use adaptive immune resistance, which takes the natural physiology of PD-L1 induction (protection of immune-mediated damage from infections) and adapts it to anti-tumor responses. When PD-L1 engages with PD-1, the T-cell function becomes inhibited; pembrolizumab blocks the PD-1: PDL-1 complex formation, allowing improved T-cell mediated killing[1-2].
Toxicology
Besides infusion reactions, most of the adverse events (AEs) are thought to be immune-related AEs. Grade 3–4 AEs only occur in up to 5% of patients. These immune-related AEs can occur in any organ. Because the optimal duration of treatment is undefined, pembrolizumab may be given for up to 2 y. Hence, immune-related AEs can occur late or even after cessation of treatment. To date, cases of rare life-threatening or fatal AEs have been reported after pembrolizumab, including severe skin reactions,80 and fulminant type I diabetes mellitus.81 The frequencies of AEs found in clinical trials are comparable, and are mainly observed when pembrolizumab was used at 10 mg/kg[3].
Dosage forms
Pembrolizumab is a humanized monoclonal IgG4 kappa anti-PD1 antibody. Binding of pembrolizumab to PD1 does not engage Fc receptors or activate complement, so that it is devoid of any cytotoxic activity. The 50% effective inhibitory concentration in T-cell activation assays ranges from 0.1–0.3 nM.32 It is a lyophilized powder, and reconstituted in 0.9% sodium chloride solution to a final concentration of 1–10 mg/mL for intravenous use. It is stable for 4 hours at room temperature, and 24 hours when refrigerated. It is administered as a 30-minute intravenous infusion[3].
References
[1] “Pembrolizumab Is Safe and Effective in Kaposi Sarcoma.” Cancer discovery (2022): 1183.
[2] Sidaway, Peter. “Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer.” Nature Reviews Clinical Oncology 40 1 (2024).
[3] CADTH, None. “Pembrolizumab (Keytruda).” Canadian Journal of Health Technologies 16 1 (2023): 0.
Pembrolizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Pembrolizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| Shanghai Minbiotech Co., Ltd. | +8617315815539 | CHINA | 129 | 58 | Inquiry |
| SHANDONG ZHI SHANG CHEMICAL CO.LTD | +86 18953170293 | China | 2931 | 58 | Inquiry |
| BOC Sciences | +1-631-485-4226 | United States | 19553 | 58 | Inquiry |
| Hubei Ipure Biology Co., Ltd | +8613367258412 | China | 10326 | 58 | Inquiry |
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | China | 30250 | 58 | Inquiry |
| AFINE CHEMICALS LIMITED | +86-0571-85134551 | China | 15395 | 58 | Inquiry |
| Wuhan Fortuna Chemical Co., Ltd | +86-027-59207850 | China | 5989 | 58 | Inquiry |
| Baoji Guokang Bio-Technology Co., Ltd. | 0917-3909592 13892490616 | China | 9321 | 58 | Inquiry |
Related articles
- Unveiling Lambrolizumab: A Comprehensive Insight into Its Production, Mechanism, and Clinical Implications
- Lambrolizumab,represents a groundbreaking advancement in the realm of immunotherapy drugs, primarily employed in the battle ag....
- Apr 11，2024
- Lambrolizumab: Mechanism, Biological Activities and Adverse effects
- Lambrolizumab is a PD-1 blocking antibody used to treat various types of cancer.
- Mar 21，2023
- Lambrolizumab: Mechanism, Bioactivity and Toxiological Studies
- Pembrolizumabis a PD-1 inhibitor that has shown clinical activity in a variety of solid tumors.
- Jan 4，2023